857 Global Regulatory Pathways A271cb0e

Global Regulatory Pathways

International regulatory requirements for medical devices beyond FDA and EU MDR markets.

Table of Contents

• Canada (Health Canada)
• Japan (PMDA)
• China (NMPA)
• Australia (TGA)
• Brazil (ANVISA)
• Market Entry Strategy

Canada (Health Canada)

Device Classification

Medical Device License (MDL) Requirements

Class II-IV Devices:

1. Device license application via MDALL (Medical Devices Active License Listing)
2. Quality management system documentation (ISO 13485)
3. Device safety and effectiveness evidence
4. Canadian labeling requirements (French/English bilingual)
5. Canadian Medical Device Single Audit Program (CMDCAS) certificate

Review Timelines:

Key Requirements

Japan (PMDA)

Device Classification (Pharmaceutical and Medical Device Act)

Shonin Approval Process

Pre-Application:

1. Classification consultation with PMDA
2. Pre-submission meeting (recommended for Class III/IV)
3. Japanese clinical data requirements assessment
4. Marketing Authorization Holder (MAH) designation

Application Requirements:

• Technical documentation per MHLW format
• Japanese clinical data (bridging study may be required)
• QMS compliance certificate (ISO 13485)
• GCP compliance for clinical studies
• Japanese labeling and IFU

Review Timelines:

Special Considerations

China (NMPA)

Device Classification

Registration Requirements

Class II/III Registration:

1. Clinical evaluation or trial (China-specific requirements)
2. Product technical requirements document
3. Type testing by NMPA-designated lab
4. Quality management system (ISO 13485 + Chinese requirements)
5. Chinese agent appointment (CSRC holder)

Review Process:

Key Requirements

China Clinical Trial Requirements

Australia (TGA)

Device Classification (TGO 41)

Australian Register of Therapeutic Goods (ARTG)

Registration Requirements:

1. Australian sponsor (manufacturer or importer)
2. Conformity assessment evidence (EU certificate or MDSAP)
3. Australian labeling compliance
4. Adverse event reporting system
5. ARTG application and fees

Pathways:

Key Requirements

Brazil (ANVISA)

Device Classification (RDC 185/2001)

Registration Process

Cadastro (Class I/II):

• Brazilian Registration Holder (BRH) application
• Technical documentation
• Good Manufacturing Practice (GMP) certificate
• Free sale certificate from country of origin

Registro (Class III/IV):

• Full technical dossier submission
• ANVISA GMP inspection (if not MDSAP)
• Clinical data requirements
• Brazilian labeling and IFU
• Registration validity: 5 years (Class III) or 10 years (Class IV)

Key Requirements

Review Timelines:

Market Entry Strategy

Prioritization Framework

Recommended Entry Sequence

Phase 1: Priority Markets (Year 1)

• United States (FDA)
• European Union (MDR)
• Leverage for downstream approvals

Phase 2: Recognition Markets (Year 1-2)

• Australia (TGA) - accepts EU/MDSAP
• Canada (Health Canada) - MDSAP pathway
• Faster approval using existing evidence

Phase 3: Major Markets (Year 2-3)

• Japan (PMDA) - may require local clinical
• China (NMPA) - local testing and clinical

Phase 4: Emerging Markets (Year 3+)

• Brazil (ANVISA)
• Other Latin America
• Middle East, Southeast Asia

Documentation Efficiency

Common Pitfalls